Metabolism open最新文献

{"title":"Evaluation of liver function biomarkers, blood pressure, and anthropometric parameters among chronic kidney disease patients: Laboratory-based cross-sectional study in Northwest Ethiopia","authors":"Melaku Mekonnen Agidew ,&nbsp;Endeshaw Chekol Abebe ,&nbsp;Zelalem Tilahun Muche ,&nbsp;Misganaw Asmamaw Mengstie ,&nbsp;Anemut Tilahun Mulu ,&nbsp;Fitalew Tadele Admasu ,&nbsp;Awgichew Behaile Teklemariam ,&nbsp;Edgiet Abebe Zewde ,&nbsp;Gelagey Baye Temesgen ,&nbsp;TeklieMengie Ayele ,&nbsp;Achenef Bogale Kassie ,&nbsp;Nega Dagnew Baye ,&nbsp;Tadesse Asmamaw Dejenie","doi":"10.1016/j.metop.2023.100254","DOIUrl":"10.1016/j.metop.2023.100254","url":null,"abstract":"<div><h3>Background</h3><p>Chronic kidney disease (CKD) is a non-communicable disease leading to a progressive decline in kidney functions and complications like liver disorders. Serum levels of liver parameters such as aminotransferases and bilirubin are important biomarkers for the diagnosis of liver diseases. Studies on the effect of CKD with and without end-stage renal disease (ESRD) on the levels of liver biomarkers in Ethiopia are limited. Hence, this study aimed to assess liver biomarkers, blood pressure (BP) and anthropometric indices in CKD patients attending a renal clinic of Felege Hiwot Comprehensive Specialized Hospital(FHCSH) in Bahir Dar, Ethiopia.</p></div><div><h3>Method</h3><p>A hospital-based cross-sectional study was conducted among 100 CKD patients attending the renal clinic of FHCSH in Bahir Dar, Ethiopia. Data were collected using a structured questionnaire through face-to-face interview. BP and anthropometric parameters were measured based on the standard procedures. About 5 ml of serum was used to analyzeliver parameter using automated chemistry analyzer. All data analyses such as independent sample t-testand one-way ANOVA were done using SPSS version 25.0. Besides, Pearson’s correlation analysis and multiple linear regression were done to identify predictors of liver biomarkers in CKD patients. P-value&lt; 0.05 were considered statistically significant.</p></div><div><h3>Results</h3><p>The mean serum levels of AST and ALT were significantly lower in CKD patients under dialysis when compared to CKD patients with no dialysis (<em>p</em> &lt; 0.05). These enzymes were positively and negatively correlated with eGFRand the severity of CKD, respectively. However, there were no significant differences in bilirubin level between different stages of CKD. There was also a significant increase (p &lt; 0.05) in the levels of AST and ALT with BMI.There was also a significant rise of SBP and DBP in CKD patients under dialysis compared to CKD patients not in dialysis.</p></div><div><h3>Conclusion</h3><p>Aminotransferases were significantly lower in CKD patients undergoing dialysis than in CKD patients not undergoing dialysis, warranting the need fora separate standard reference ranges or using other diagnostic criteria to diagnose liver comorbidities in CKD patients. The levels of AST and ALT in CKD patients were also significantly increased with BMI. Besides, BP was significantly elevated with the severity of CKD, indicating the more advanced the CKD is, the higher BP.</p></div>","PeriodicalId":94141,"journal":{"name":"Metabolism open","volume":"19 ","pages":"Article 100254"},"PeriodicalIF":0.0,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/ad/31/main.PMC10480547.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10189856","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effect of finerenone on diabetic kidney disease outcomes with estimated glomerular filtration rate below 25 mL/min/1.73 m2","authors":"Akira Mima,&nbsp;Rina Lee,&nbsp;Ami Murakami,&nbsp;Hidemasa Gotoda,&nbsp;Ryosuke Akai,&nbsp;Sayumi Kidooka,&nbsp;Takahiro Nakamoto,&nbsp;Suguru Kido,&nbsp;Shinji Lee","doi":"10.1016/j.metop.2023.100251","DOIUrl":"https://doi.org/10.1016/j.metop.2023.100251","url":null,"abstract":"<div><h3>Background</h3><p>In the Finerenone in Reducing Cardiovascular Mortality and Morbidity in Diabetic Kidney Disease trial, finerenone reduced the risk of cardiovascular events in patients with chronic kidney disease (CKD) and type 2 diabetes, while in the Finerenone in Reducing Kidney Failure and Disease Progression in Diabetic Kidney Disease trial, it improved renal and cardiovascular outcomes in patients with advanced CKD. However, no previous studies have assessed patients with CKD and type 2 diabetes with an estimated glomerular filtration rate (eGFR) below 25 mL/min/1.73 m²</p></div><div><h3>Methods</h3><p>Nine patients with CKD and type 2 diabetes who received finerenone 10 mg/day were analyzed retrospectively. Changes in eGFR, urinary protein, and serum potassium levels were studied from 1 year before administration of finerenone until 6 months after administration.</p></div><div><h3>Results</h3><p>The mean baseline eGFR slope was −7.63 ± 9.84 (mL/min/1.73 m²/year). After finerenone treatment, the mean eGFR slope significantly improved −1.44 ± 3.17 (mL/min/1.73 m²/6 months, <em>P</em>=0.038). However, finerenone treatment did not significantly reduce proteinuria. Furthermore, finerenone did not increase serum potassium levels.</p></div><div><h3>Conclusions</h3><p>Patients treated with finerenone showed a significantly slower decline in eGFR. Furthermore, aside from the present study, no reports have indicated the effectiveness of finerenone in patients with advanced CKD with an eGFR below 25 mL/min/1.73 m². As confirmed in our clinical trials, the finding that finerenone is effective in a wide range of renal functions can be generalized to clinical practice. However, sample size in this study was small. Thus, further large-scale investigations will be needed.</p></div>","PeriodicalId":94141,"journal":{"name":"Metabolism open","volume":"19 ","pages":"Article 100251"},"PeriodicalIF":0.0,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"50199253","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Longitudinal changes in pancreatic volume and pancreatic fat with weight gain in Japanese without diabetes: An analysis using health check-up data","authors":"Maria Sunouchi ,&nbsp;Jun Inaishi ,&nbsp;Ryoko Shimizu-Hirota ,&nbsp;Yoshifumi Saisho ,&nbsp;Kaori Hayashi ,&nbsp;Hiromasa Takaishi ,&nbsp;Hiroshi Itoh","doi":"10.1016/j.metop.2023.100250","DOIUrl":"10.1016/j.metop.2023.100250","url":null,"abstract":"<div><h3>Aims/introduction</h3><p>There have been few reports about the longitudinal changes in pancreas volume (PV) or pancreatic steatosis (PS) in response to obesity. In this longitudinal analysis using health check-up data, we explored changes in PV, PS and glucose metabolic indices that occurred after weight gain in Japanese without diabetes.</p></div><div><h3>Materials/methods</h3><p>Clinical data on 37 Japanese subjects with a ≥1 kg/m² increase in body mass index between two health check-ups and without diabetes were collected. PV, pancreas attenuation (PA) and splenic attenuation (SA) were evaluated using computed tomography (CT) images. The pancreas area was outlined by hand in multiple images with slice thickness of 2 mm, and the PV was computed by summing these areas. PS was defined as the difference between SA and PA (SA-PA). Medical records were collected, including findings on immunoreactive insulin (IRI), homeostasis model assessment of insulin resistance (HOMA-R) and beta cell function (HOMA-β). Paired <em>t</em>-test and Spearman's correlation coefficient were used in the analyses.</p></div><div><h3>Results</h3><p>The median follow-up period was 21.1 months and the mean BMI was increased from 25.5 ± 3.3 kg/m² to 27.0 ± 3.3 kg/m². PV (53.5 ± 15.9 cm³ vs. 56.2 ± 16.4 cm³) and SA-PA (8.7 ± 9.1 HU vs. 13.6 ± 10.9 HU) increased significantly after weight gain (both, P &lt; 0.001). There were significant increases of IRI and HOMA-R with the weight gain (both, P &lt; 0.05), whereas HOMA-β exhibited only a nonsignificant trend of increase (55.4％ (41.5-65.5) vs. 56.8％ (46.2-83.7), P = 0.07).</p></div><div><h3>Conclusions</h3><p>Both PV and PS were increased longitudinally with weight gain in Japanese without diabetes.</p></div>","PeriodicalId":94141,"journal":{"name":"Metabolism open","volume":"19 ","pages":"Article 100250"},"PeriodicalIF":0.0,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/41/3c/main.PMC10314282.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9745542","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effects of fructose added to an oral glucose tolerance test on plasma glucose excursions in healthy adults","authors":"Amée M. Buziau ,&nbsp;Jean L.J.M. Scheijen ,&nbsp;Coen D.A. Stehouwer ,&nbsp;Casper G. Schalkwijk ,&nbsp;Martijn C.G.J. Brouwers","doi":"10.1016/j.metop.2023.100245","DOIUrl":"10.1016/j.metop.2023.100245","url":null,"abstract":"<div><h3>Background and objective</h3><p>Previous experimental studies have shown that fructose interacts with glucose metabolism by increasing hepatic glucose uptake. However, human studies investigating the effects of small (‘catalytic’) amounts of fructose, added to an oral glucose load, on plasma glucose levels remain inconclusive. The aim of this study, therefore, was to repeat and extend these previous studies by examining the plasma glucose response during a 75 g oral glucose tolerance test (OGTT) with the addition of different doses of fructose.</p></div><div><h3>Methods</h3><p>Healthy adults (n = 13) received an OGTT without addition of fructose and OGTTs with addition of different doses of fructose (1, 2, 5, 7.5 and 15 g) in a random order, on six separate occasions. Plasma glucose levels were measured every 15 min for 120 min during the study<strong>.</strong></p></div><div><h3>Findings</h3><p>The plasma glucose incremental area under the curve (iAUC) of the OGTT without addition of fructose was not significantly different from any OGTT with fructose (p ≥ 0.2 for all fructose doses). Similar results were observed when these data were clustered with data from a similar, previous study (pooled mean difference: 10.6; 95%CI: 45.0; 23.8 for plasma glucose iAUC of the OGTT without addition of fructose versus an OGTT with 5 g fructose; fixed-effect meta-analysis, n = 38). Of interest, serum fructose increased from 4.8 μmol/L (interquartile range: 4.1–5.9) at baseline to 5.3 μmol/L (interquartile range: 4.8–7.5) at T = 60 min during an OGTT <em>without</em> addition of fructose (p = 0.002).</p></div><div><h3>Conclusion</h3><p>Low doses of fructose added to an OGTT do not affect plasma glucose levels in healthy adults. The role of endogenous fructose production, as a potential explanation of these null-findings, deserves further investigation.</p></div>","PeriodicalId":94141,"journal":{"name":"Metabolism open","volume":"18 ","pages":"Article 100245"},"PeriodicalIF":0.0,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10209703/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9550483","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association between personality traits and glycemic control after inpatient diabetes education","authors":"Taisuke Uchida ,&nbsp;Hiroaki Ueno ,&nbsp;Ayaka Konagata ,&nbsp;Takayuki Nakamura ,&nbsp;Norifumi Taniguchi ,&nbsp;Hiroki Nabekura ,&nbsp;Fumiko Kogo ,&nbsp;Yuma Nagatomo ,&nbsp;Yuri Tanaka ,&nbsp;Koichiro Shimizu ,&nbsp;Tomomi Shiiya ,&nbsp;Hideki Yamaguchi ,&nbsp;Kazuya Shimoda","doi":"10.1016/j.metop.2023.100244","DOIUrl":"10.1016/j.metop.2023.100244","url":null,"abstract":"<div><h3>Aims</h3><p>The longitudinal effect of personality traits on glycemic control is unclear. This prospective observational study explored the relationship between personality traits and glycemic control in patients with uncontrolled diabetes after inpatient diabetes education.</p></div><div><h3>Methods</h3><p>Patients with diabetes mellitus (HbA1c ≥ 7.5%, measured by high-performance liquid chromatography) who received inpatient diabetes education were scored on the Big Five personality traits: neuroticism, extraversion, openness, agreeableness, and conscientiousness. Multiple linear analysis was used to determine whether any personality traits were independently associated with HbA1c on admission and HbA1c change from admission to 1, 3, and 6 months after discharge.</p></div><div><h3>Results</h3><p>One hundred seventeen participants (mean age 60.4 ± 14.5 years; 59.0% male) were enrolled. HbA1c values on admission and 1, 3, and 6 months after discharge were 10.2 ± 2.1%, 8.3 ± 1.4%, 7.6 ± 1.4%, and 7.7 ± 1.5%, respectively. Multiple linear analysis showed that no personality traits were associated with HbA1c on admission. Neuroticism was negatively associated with the HbA1c change from admission to 3 months (β = −0.192, <em>P</em> = 0.025) and 6 months after discharge (β = −0.164, <em>P</em> = 0.043).</p></div><div><h3>Conclusions</h3><p>Neuroticism was associated with good long-term glycemic control after inpatient diabetes education.</p></div>","PeriodicalId":94141,"journal":{"name":"Metabolism open","volume":"18 ","pages":"Article 100244"},"PeriodicalIF":0.0,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10313504/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9742928","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparative assessment of hepatoprotective properties of Artesunate and flavonoids from Artemisia annua on acetaminophen and carbon tetrachloride-induced cytotoxicity in primary mice hepatocytes","authors":"Marie Ange Djeungoue Petga ,&nbsp;Arnaud Fondjo Kouam ,&nbsp;Rosine Désirée Chougouo Kengne ,&nbsp;Boris Rosnay Galani Tietcheu ,&nbsp;Josué Simo Louokdom ,&nbsp;Claude Bérenger Ngantchouko Ngalemo ,&nbsp;Pascal Dieudonné Chuisseu Djamen ,&nbsp;Paul Fewou Moundipa","doi":"10.1016/j.metop.2023.100241","DOIUrl":"https://doi.org/10.1016/j.metop.2023.100241","url":null,"abstract":"<div><h3>Background</h3><p>Artesunate (ART) is a semi-synthetized molecule from Artemisinin, an active compound isolated from the medicinal plant <em>Artemisia annua</em>, widely used for the treatment of malaria. Previous studies reported that ART may exert a dual effect on the liver. Accordingly, this study investigated the potential protective action of ART against Acetaminophen (APAP) and Carbon tetrachloride (CCl₄)-induced hepatotoxicity in primary mice hepatocytes, in comparison to that of flavonoid extracted from <em>A. annua</em> (FAA). In addition, the antioxidant properties of FAA were also assessed.</p></div><div><h3>Methods</h3><p>The antioxidant activities of FAA and Ascorbic acid (ASC) (0.01–100 μg/mL) were assessed through inhibition of lipid peroxidation, reduction of ferric and phosphomolydenum, and hydroxyl and DPPH radicals scavenging assays. The hepatoprotective effects of FAA and ART (0.1–100 μg/mL) were evaluated against APAP (11 mM) or CCl4 (4 mM) induced oxidative damage in primary mouse hepatocytes. Biochemical parameters associated with hepatotoxicity assessed include cell viability, cell membrane integrity, cellular glutathione, and antioxidant enzyme activities.</p></div><div><h3>Results</h3><p>The obtained finding revealed FAA displayed a remarkable antioxidant activities as evidenced by the low IC₅₀/EC₅₀ values (3.85–19.32 μg/mL), comparable to that of ASC (3.26–18.04 μg/mL). When tested at 10 μg/mL, both FAA and ART significantly (p˂0.05) preserved cell viability, inhibited alanine aminotransferase leakage and lipid membrane peroxidation, and restored superoxide dismutase and catalase activities and glutathione content induced by APAP or CCl₄ in a similar way as Silymarin. However, ART showed a significant (p˂0.05) cytotoxic effect on hepatocytes at 100 and 1000 μg/mL and did not confer obvious protection at 100 μg/mL.</p></div><div><h3>Conclusion</h3><p>Overall, our data demonstrated that ART harms mice hepatocytes at high concentration while conferring relative protection against APAP and CCl₄-hepatotoxicity at low concentration. In contrast, FAA effectively protects liver cells without cytotoxicity effect, event at 100 μg/mL. Accordingly, ART should be given to the patient only under a medical prescription.</p></div>","PeriodicalId":94141,"journal":{"name":"Metabolism open","volume":"18 ","pages":"Article 100241"},"PeriodicalIF":0.0,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"50199352","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Ferroptosis in diabetic nephropathy: Mechanisms and therapeutic implications","authors":"Misganaw Asmamaw Mengstie ,&nbsp;Mohammed Abdu Seid ,&nbsp;Natnael Atnafu Gebeyehu ,&nbsp;Getachew Asmare Adella ,&nbsp;Gizchew Ambaw Kassie ,&nbsp;Wubet Alebachew Bayih ,&nbsp;Molalegn Mesele Gesese ,&nbsp;Denekew Tenaw Anley ,&nbsp;Sefineh Fenta Feleke ,&nbsp;Melkamu Aderajew Zemene ,&nbsp;Anteneh Mengist Dessie ,&nbsp;Yenealem Solomon ,&nbsp;Berihun Bantie ,&nbsp;Tadesse Asmamaw Dejenie ,&nbsp;Assefa Agegnehu Teshome ,&nbsp;Endeshaw Chekol Abebe","doi":"10.1016/j.metop.2023.100243","DOIUrl":"10.1016/j.metop.2023.100243","url":null,"abstract":"<div><p>Diabetic Nephropathy (DN), the most common complication in diabetes mellitus, has been affecting the lives of people diabetic for a long time. Numerous studies have demonstrated the unbreakable connection between ferroptosis and kidney cell damage. Ferroptosis is a type of iron-dependent, non-apoptotic, regulated cell death, characterized by the buildup of intracellular lipid peroxides to lethal levels. Although the role of programmed cell deaths like apoptosis, autophagy, and necroptosis in the pathogenesis of DN has been demonstrated, the implication of ferroptosis in DN was least interrogated. Hence, the main aim of this review was to discuss the current understanding of ferroptosis focusing on its potential mechanisms, its involvement in DN, and emerging therapeutic opportunities.</p></div>","PeriodicalId":94141,"journal":{"name":"Metabolism open","volume":"18 ","pages":"Article 100243"},"PeriodicalIF":0.0,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/ef/53/main.PMC10130620.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9386553","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Energetic homeostasis achieved through biophoton energy and accompanying medication treatment resulted in sustained levels of Thyroiditis-Hashimoto's, iron, vitamin D & vitamin B12","authors":"Mariola A. Smotrys ,&nbsp;James Z. Liu ,&nbsp;Suzanne Street ,&nbsp;Seth Robinson","doi":"10.1016/j.metop.2023.100248","DOIUrl":"10.1016/j.metop.2023.100248","url":null,"abstract":"<div><p>We present the case of a 37-year-old premenopausal woman, who presented with fatigue, weakness, pallor, and myalgias. She was on treatment for Hashimoto's Thyroiditis, iron deficiency anemia, deficiency of vitamin D and B12. Further diagnostic workup revealed her anemia was attributed to a long history of menorrhagia, deficiency of vitamin D and B12 which was attributed to Celiac disease. Her overall health improved with daily medication and by being around the biophoton generators, a device-generated biophoton field. Supplemental exposure to biophoton energy stabilized her blood component levels and improved the functional and energetic conditions of all her organs and systems.</p></div>","PeriodicalId":94141,"journal":{"name":"Metabolism open","volume":"18 ","pages":"Article 100248"},"PeriodicalIF":0.0,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/c1/12/main.PMC10251148.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9617593","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"SENP2 knockdown in human adipocytes reduces glucose metabolism and lipid accumulation, while increases lipid oxidation","authors":"Solveig A. Krapf ,&nbsp;Jenny Lund ,&nbsp;Hege G. Bakke ,&nbsp;Tuula A. Nyman ,&nbsp;Stefano Bartesaghi ,&nbsp;Xiao-Rong Peng ,&nbsp;Arild C. Rustan ,&nbsp;G. Hege Thoresen ,&nbsp;Eili T. Kase","doi":"10.1016/j.metop.2023.100234","DOIUrl":"10.1016/j.metop.2023.100234","url":null,"abstract":"<div><p>Adipose tissue is one of the main regulative sites for energy metabolism. Excess lipid storage and expansion of white adipose tissue (WAT) is the primary contributor to obesity, a strong predisposing factor for development of insulin resistance. Sentrin-specific protease (SENP) 2 has been shown to play a role in metabolism in murine fat and skeletal muscle cells, and we have previously demonstrated its role in energy metabolism of human skeletal muscle cells. In the present work, we have investigated the impact of SENP2 on fatty acid and glucose metabolism in primary human fat cells by using cultured primary human adipocytes to knock down the SENP2 gene. Glucose uptake and oxidation, as well as accumulation and distribution of oleic acid into complex lipids were decreased, while oleic acid oxidation was increased in SENP2-knockdown cells compared to control adipocytes. Furthermore, lipogenesis was reduced by SENP2-knockdown in adipocytes. Although TAG accumulation relative to total uptake was unchanged, there was increased mRNA expression of metabolically relevant genes such as <em>UCP1</em> and <em>PPARGC1A</em> and mRNA and proteomic data revealed increased levels of mRNA and proteins related to mitochondrial function by SENP2-knockdown. In conclusion, SENP2 is an important regulator of energy metabolism in primary human adipocytes and its knockdown reduce glucose metabolism and lipid accumulation, while increasing lipid oxidation in human adipocytes.</p></div>","PeriodicalId":94141,"journal":{"name":"Metabolism open","volume":"18 ","pages":"Article 100234"},"PeriodicalIF":0.0,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10066554/pdf/main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9240892","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Differential metabolic host response to pathogens associated with community-acquired pneumonia","authors":"Ilona den Hartog ,&nbsp;Naama Karu ,&nbsp;Laura B. Zwep ,&nbsp;G. Paul Voorn ,&nbsp;Ewoudt M.W. van de Garde ,&nbsp;Thomas Hankemeier ,&nbsp;J.G. Coen van Hasselt","doi":"10.1016/j.metop.2023.100239","DOIUrl":"10.1016/j.metop.2023.100239","url":null,"abstract":"<div><h3>Background</h3><p>Metabolic changes induced by the host immune response to pathogens found in patients with community-acquired pneumonia (CAP) may provide insight into its pathogenesis. In this study, we characterized differences in the host metabolic response to common CAP-associated pathogens.</p></div><div><h3>Method</h3><p>Targeted metabolomic profiling was performed on serum samples obtained from hospitalized CAP patients (n = 119) at admission. We quantified 347 unique metabolites across multiple biochemical classes, including amines, acylcarnitines, and signaling lipids. We evaluated if unique associations between metabolite levels and specific CAP-associated pathogens could be identified.</p></div><div><h3>Results</h3><p>Several acylcarnitines were found to be elevated in <em>C. burnetii</em> and herpes simplex virus and lowered in <em>M. pneumoniae</em> as compared to other pathogens. Phenylalanine and kynurenine were found elevated in <em>L. pneumophila</em> as compared to other pathogens. S-methylcysteine was elevated in patients with <em>M. pneumoniae</em>, and these patients also showed lowered cortisol levels in comparison to almost all other pathogens. For the herpes simplex virus, we observed a unique elevation of eicosanoids and several amines. Many lysophosphatidylcholines showed an altered profile in <em>C. burnetii</em> versus S<em>. pneumoniae, L. pneumophila,</em> and respiratory syncytial virus. Finally, phosphatidylcholines were negatively affected by the influenza virus in comparison to <em>S. pneumoniae</em>.</p></div><div><h3>Conclusions</h3><p>In this exploratory analysis, metabolites from different biochemical classes were found to be altered in serum samples from patients with different CAP-associated pathogens, which may be used for hypothesis generation in studies on differences in pathogen host response and pathogenesis of CAP.</p></div>","PeriodicalId":94141,"journal":{"name":"Metabolism open","volume":"18 ","pages":"Article 100239"},"PeriodicalIF":0.0,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10070890/pdf/main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9264100","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}